Fri, May 9, 9:28 PM (13 days ago)
### Actinium Pharmaceuticals, Inc. (ATNM) Q1 2025 Financial Summary **Financial Health and Performance Metrics:** - **Revenue:** No commercial revenue reported for Q1 2025 and Q1 2024. - **Profit Margins:** Net loss of $15.9 million for Q1 2025, compared to $8.7 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $7.6 million for Q1 2025, an increase of $0.2 million from Q1 2024. - **Earnings Changes:** Net loss per share increased to $0.51 for Q1 2025 from $0.31 in Q1 2024. **Quarterly Performance Discussion:** - **Operating Expenses:** Total operating expenses were $16.6 million for Q1 2025, up from $9.6 million in Q1 2024, primarily due to higher non-cash stock-based compensation and increased preclinical expenses. - **General and Administrative Expenses:** Increased by $5.9 million due to higher non-cash stock-based compensation. - **Research and Development Expenses:** Increased by $1.1 million due to higher non-cash stock-based compensation and preclinical expenses. **Trends and Uncertainties:** - **Stock-Based Compensation:** Significant non-cash stock compensation expense recorded in Q1 2025. - **Workforce Optimization:** Reduction in headcount by approximately 14%, expected to reduce personnel-related expenses by $1.15 million for the remainder of 2025. - **Future Operations Impact:** Continued reliance on third-party manufacturers and suppliers for isotopes and other components. **Future Outlook:** - **Funding:** Expects existing resources to be sufficient to fund planned operations for more than 12 months. - **Clinical Trials:** Ongoing and planned clinical trials for Actimab-A, Iomab-ACT, and ATNM-400. - **Regulatory Approvals:** Uncertainties related to FDA approvals and potential additional trials required for Iomab-B. **Key Risks:** - **Clinical Trial Risks:** Dependence on third-party contractors and potential delays or failures in clinical trials. - **Regulatory Risks:** Uncertainties related to FDA approvals and potential additional trials required for Iomab-B. - **Market Risks:** Competition from other biotechnology and pharmaceutical companies. **Conclusion:** Actinium Pharmaceuticals, Inc. reported a net loss of $15.9 million for Q1 2025, with significant increases in operating and general administrative expenses. The company continues to face uncertainties related to regulatory approvals and clinical trials, but expects existing resources to be sufficient to fund planned operations for the next 12 months. The reduction in headcount is expected to reduce personnel-related expenses, but the company remains dependent on third-party manufacturers and suppliers.